Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review | Zendy

Rimda Wanchoo | Zendy; Sabine Karam | Zendy; Nupur N. Uppal | Zendy; Valerie S. Barta | Zendy; Gilbert Deray | Zendy; Craig Devoe | Zendy; Vincent LaunayVacher | Zendy; Kenar D. Jhaveri | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Author(s) -

Rimda Wanchoo,

Sabine Karam,

Nupur N. Uppal,

Valerie S. Barta,

Gilbert Deray,

Craig Devoe,

Vincent LaunayVacher,

Kenar D. Jhaveri

Publication year - 2017

Publication title -

american journal of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 85

eISSN - 1421-9670

pISSN - 0250-8095

DOI - 10.1159/000455014

Subject(s) - medicine , ipilimumab , nivolumab , pembrolizumab , adverse effect , kidney cancer , atezolizumab , cancer , oncology , gastroenterology , immunology , immunotherapy

Cancer immunotherapy, such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death 1 (PD-1), has revolutionized the treatment of malignancies by engaging the patient's own immune system against the tumor rather than targeting the cancer directly. These therapies have demonstrated a significant benefit in the treatment of melanomas and other cancers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research